Key Highlights
- Glaukos Corporation (NYSE:GKOS) traded at USD 210.01, up 15.75%, in pre-market trading on Thursday, October 29, 2026, after the company's release of Wednesday, October 28, 2026 reported record third quarter net sales and a raised full-year outlook.
- Third quarter 2026 net sales were USD 211.0 million, up 58% from USD 133.5 million a year earlier, with GAAP Net Income of USD 2.0 million, or USD 0.03 per diluted share.
- Full-year 2026 net sales guidance was raised to USD 775 million to USD 785 million from USD 680 million to USD 700 million, and preliminary 2027 net sales guidance was set at USD 1 billion.
- Cash, short-term investments and restricted cash totalled USD 339.8 million at Wednesday, September 30, 2026 and the company reports no debt. Pre-market quotes are thinly traded and can change before the open.
The Pre-Market Move and Its Catalyst
Glaukos Corporation (NYSE:GKOS), a medical technology company that develops therapies for glaucoma and corneal disease, traded at USD 210.01, up 15.75%, in pre-market trading on Thursday, October 29, 2026. The move followed the company's Earnings release of Wednesday, October 28, 2026, which reported record third quarter net sales and raised full-year 2026 net sales guidance to USD 775 million to USD 785 million from USD 680 million to USD 700 million. The release also set preliminary 2027 net sales guidance at USD 1 billion, based on the latest foreign currency exchange rates. Pre-market quotes reflect thin Liquidity and can change before the open at 9:30 a.m. ET. The reaction is therefore a repricing of expected Revenue rather than of a single quarter.
How the Latest Results Frame the Move
Glaukos Corporation (NYSE:GKOS) reported third quarter net sales of USD 211.0 million, up 58% in reported and constant currency from USD 133.5 million. U.S. Glaucoma sales were USD 118.6 million (up 47%) while Corneal Health sales were USD 59.0 million (up 154%) and International Glaucoma sales were USD 33.4 million (up 13.3%). GAAP gross Margin was 85.2% against 78.4%, and non-GAAP gross margin was 87.7% against 83.9%. GAAP net income was USD 2.0 million against a loss of USD 16.2 million, and non-GAAP net income was USD 28.5 million, or USD 0.47 per diluted share. The release credits iDose TR, a long-duration implant that delivers glaucoma medication inside the eye, and Epioxa, a corneal therapy, as the growth drivers. Simple arithmetic on the two guidance ranges shows the midpoint rising by USD 90 million.
Risks and What to Watch
Glaukos Corporation (NYSE:GKOS) presents a bull reading in which two launches sustain growth above 50% while gross margin expands, which would support the USD 1 billion preliminary 2027 figure. The bear reading rests on thin profitability, since GAAP income from operations was only USD 0.8 million, and on dependence on two products for most incremental sales. International Glaucoma sales fell 8.9% from the prior quarter, and the 2027 figure is preliminary and sensitive to currency rates. A gain of this size also raises the bar for the next report. Investors should watch the 9:30 a.m. ET open on Thursday, October 29, 2026, the remarks that accompany the results release and the quarterly filing for the period ended Wednesday, September 30, 2026.
Where Things Stand
The answer is that Glaukos Corporation (NYSE:GKOS) rose 15.75% pre-market because its release of Wednesday, October 28, 2026 combined a 58% increase in third quarter net sales with a guidance raise of roughly USD 90 million at the midpoint. The pre-market price was USD 210.01. The next catalysts are the 9:30 a.m. ET open on Thursday, October 29, 2026, the quarterly filing for the period ended Wednesday, September 30, 2026 and any further commentary on 2027 planning. Pre-market prices are snapshots and can change, and this is not Investment advice.






Please wait processing your request...